# Regulatory strategy
> Regulatory strategy defines the pathways, evidence, submissions and authority interactions used to obtain and maintain product authorisation across target markets.
Source: https://www.visfo.health/glossary/regulatory-strategy
Updated: 2026-08-16T21:55:00.883858+00:00

What is regulatory strategy?
Regulatory strategy is the plan for obtaining and maintaining authorisation for a medicine, device or other regulated product in its target markets. It defines the regulatory pathways, submission formats, data requirements and authority interactions the organisation intends to pursue.

The strategy connects the proposed indication, patient population, claims and label with the evidence needed to support them. It also addresses expedited pathways where relevant, regional differences, submission timing, post-authorisation commitments and future lifecycle changes.

Why does regulatory strategy matter in regulatory planning?
Regulatory strategy turns development ambitions into an executable route to approval. It helps teams identify evidence gaps, dependencies and authority concerns early enough to address them, reducing avoidable submission risk and delays. It can also shorten time to market where an appropriate expedited pathway or more efficient submission sequence is available.

The decisions affect more than the regulatory function. They shape [clinical development](/glossary/clinical-development), evidence generation, manufacturing readiness, labelling, medical plans and preparations for market access. Early alignment between Regulatory, Clinical, Medical, Safety, Access, Commercial and operational teams is therefore essential.

How is a regulatory strategy developed and run in practice?
Teams usually begin with the intended product profile and the markets in which authorisation will be sought. They then translate the desired indication and label into evidence, procedural and operational requirements.

A practical strategy will normally set out:
- the target indications, populations, claims and proposed label;
- the planned pathway and submission type in each market;
- the clinical, non-clinical, quality and safety evidence required;
- known evidence gaps, regulatory risks and mitigation actions;
- planned authority meetings, scientific advice and other interactions;
- the sequence and timing of regional submissions relative to development milestones;
- responsibilities, decision points and contingency options;
- likely post-authorisation studies, safety activities and lifecycle submissions.

The strategy should be reviewed when evidence changes, authority feedback is received or development assumptions no longer hold. It is a living decision framework rather than a document produced once for a submission.

How are global and regional regulatory strategies aligned?
A global strategy defines the common evidence base, core positioning and preferred submission sequence. Regional strategies adapt that plan to local classifications, procedures, formats, data expectations, labelling conventions and authority priorities. The aim is not to make every submission identical, but to preserve a coherent product rationale while meeting each market’s requirements.

Teams should identify regional divergence early. A local requirement may affect trial design, comparator choice, endpoints, manufacturing data or follow-up periods across the wider programme. Early authority engagement can test assumptions, but advice from one authority should not automatically be treated as applicable elsewhere.

Who owns regulatory strategy, and where do teams go wrong?
Regulatory Affairs normally leads the strategy and coordinates authority engagement, but it cannot develop it in isolation. Clinical, Safety, Biostatistics, Quality, Manufacturing and Medical teams contribute the evidence and feasibility assessment. Access and Commercial teams clarify the intended populations, value proposition and launch priorities without replacing regulatory judgement.

Common problems include treating the strategy as a submission timetable, seeking advice without clear decision questions, overlooking regional differences, or pursuing label ambitions that the planned studies cannot support. Another failure is separating regulatory evidence needs from the wider [Evidence generation programme](/glossary/evidence-generation-program). Good practice keeps assumptions explicit, assigns owners to risks and records how authority feedback changes the plan.

How does regulatory strategy differ from adjacent planning terms?
Regulatory strategy explains how the product will meet authority requirements and secure or maintain authorisation. [Clinical development](/glossary/clinical-development) is the broader programme that tests safety, efficacy and appropriate use, while an evidence generation programme coordinates evidence needs across regulatory, medical and access objectives. [Real-world evidence](/glossary/real-world-evidence-rwe) is one possible evidence source within these plans, particularly where it can support safety monitoring, commitments or lifecycle questions.

A regulatory plan or submission plan is more operational: it lists activities, documents, owners and dates. The strategy sits above it, explaining which pathway has been chosen, what evidence and interactions are needed, and how the organisation will respond if its assumptions are challenged.